Effect of Thromboxane A2 Synthetase Inhibitor on Metabolism and Contractility in Ischemic Reperfused Rabbit Heart

Abstract

The effect of thromboxane A₂ synthetase inhibitor (OKY-046) on myocardial metabolism and contractility during ischemia and reperfusion was examined by the phosphorus 31- nuclear magnetic resonance (³¹P-NMR) in Langendorff rabbit hearts with use of an arti ficial blood substitute, perfluorochemical emulsion Fluosol-43. After normothermic fifteen-minute global zero-flow ischemia or fifteen-minute global low-flow ischemia (coronary perfusion pressure = 20 mmHg), reperfusion of sixty minutes was carried out. OKY-046 was administered from forty-five minutes prior to the global ischemia. Adenosine triphosphate (ATP), creatine phosphate (CrP), inorganic phosphate (Pi), pH, left ventricular systolic developed pressure (LV Dev.P) and coronary flow were continu ously measured. Twenty-eight hearts were divided into four experimental groups consisting of 7 hearts each; Group I consisted of controls with zero-flow ischemia; Group II, perfusion with OKY-046 (10^-6 M) in zero-flow ischemia; Group III, controls with low- flow ischemia; and Group IV, perfusion with OKY-046 in low-flow ischemia. Group II showed a significant inhibition of the increase in Pi and of the decrease in ATP, CrP, and pH during global ischemia compared with Group I, and a suppression of the overshoot of CrP observed after postischemic reperfusion. Group IV also showed a significantly marked improvement of ATP, CrP, and pH and significant suppression in Pi during low-flow ischemia compared with Group III. There were no differences in LV Dev.P and coronary flow among any groups. In conclusion, OKY-046 has a significantly beneficial effect on metabolism during both myocardial ischemia and reperfusion.

Get full access to this article

View all access options for this article.

References

Szczeklik A. , Gryglewski RJ , Musial J. , et al: Arachidonic acid-induced platelet aggregation and thromboxane A2 generation in patients with coronary heart disease. Acta Biol Med Ger 37:741-742, 1978.

Lewwy RJ , Smith JB , Silver MJ , et al: Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. Prostaglandins Med 2:243-248, 1979.

Kawabata H. , Sugiyama K. , Katori R. : Effect of acetylsalicylic acid on metabolism and contractility in the ischemic reperfused heart. Jpn Circ J 60:961-971, 1996.

Gard JK , Kichura GM , Ackerman Jjh : Quantitative 31P nuclear magnetic resonance analysis of metabolite concentrations in Langendorff-perfused rabbit hearts. Biophys 48:803-813, 1985.

Freeman D. , Mayr H. , Schmidt P. , et al: Advantages of perfluorochemical perfusion in the isolated working rabbit heart preparation using 31 P-NMR. Biochim Biophys Acta 927:350-358, 1987.

Jennings RB , Reimer KA , Hill ML , et al: Total ischemia in dog hearts, in vitro. Circ Res 49:892-900, 1981.

Reimer KA, Jennings RB , Hill ML : Total ischemia in dog hearts, in vitro. Circ Res 49:901-911, 1981.

Itoh K. , Matsubara T. , Nanki M. , et al: Relationship between regional myocardial blood flow and tissue ATP content in acute ischemia. Jpn Heart J 25:599-608, 1984.

Hoffmeister HM , Mauser M. , Schaper W. : Regional function during accelerated ATP repletion after myocardial ischemia. Circulation 68:III-193, 1983.

10.

Ito T. , Ito Y. , Torii T. , et al: Protective effects of selective inhibitor of thromboxane synthetase (OKY-046) and thromboxane antagonist (ONO 3708) on ischemia-induced mitochondrial dysfunction in canine heart. Adv Prostaglandin Thromboxane Leukotriene Res 17:392-396, 1987.

11.

Moriuch M. : The efficacy of prostacyclin (PGI2) and/or OYY-046, a specific thromboxane synthetase inhibitor, in acute myocardial infarction-experimental study (in Japanese). Respir Circ 32:955-961, 1984.

12.

Ogura T. , Watanabe I. , Saitou T. , et al: Effects of OKY-046, a selective thromboxane A2 synthetase inhibitor, on ventricular arrhythmias and prostaglandins during coronary artery ligation and reperfusion in anesthetized dogs. Jpn J Pharmacol 47:95-98, 1988.

13.

Hiraku S. , Taniguchi K. , Wakitani K. , et al: Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn J Pharmacol 41:393-401, 1986.

14.

Karmazyn M. , Tani M. , Neely JR : Effect of prostaglandins I2 (prostacyclin) and F2α on function, energy metabolism, and calcium uptake in ischemic/ reperfused hearts. Cardiovasc Res 27:396-402, 1993.

15.

Alexander RW , Kent KM , Pisano JJ , et al: Regulation of postocclusive hyperemia by endogenously synthesized prostaglandins in the dog heart. J Clin Invest 55:1174-1181, 1975 .

16.

Moffat MP : Concentration-dependent effects of prostacyclin on the response of the isolated guinea pig heart to ischemia and reperfusion: Possible involvement of the slow inward current. J Pharmacol Exp Ther 242:292-299, 1987.

17.

Moffat MP , Karmazyn M. , Ferrier GR : Prostaglandins as key modulators of reperfusion-induced cardiac injury. Initial studies into possible mechanisms. In: Pathogenesis of Stress-Induced Heart Disease, ed. by Beamish RE , Panagia V , Dhalla NS. Boston: Martinus Nijhoff, 1985, pp 320-332.

18.

Karmazyn M. : Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts. Am J Physiol 251:H133-H140, 1986.

19.

Karmazyn M. : A role for prostaglandins in reperfusion-induced myocardial injury ? In: Advances in Myocardiology, vol. 6, ed. by Dhalla NS , Hearse DJ. New York: Plenum, 1985, pp 429-436.